Autopsy report · NCT01661140
A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Severe Active Rheumatoid Arthritis, Comparing Tapering Versus Maintaining the Methotrexate Dosage
Cause of deathNo reason given
Life of this trial
- Registered 1 month before it started.
- Ran for about 2 years 5 months before it stopped.
- 427 participants enrolled.
- Results were posted on the registry 1 year 8 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 4
- Sponsor
- Hoffmann-La Roche
- Sponsor type
- Industry
- Conditions
- Rheumatoid Arthritis
- Interventions
- Methotrexate (stable dose); Tocilizumab; Methotrexate (tapering dose)
- Participants
- 427
- Sites
- 67
- Countries
- United Kingdom
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.